All companies get ready to go to market. They can't be flat-footed when (if) they get approval; they want to be ready to go. I wouldn't read too much into this other than business-as-usual for pre-launch prep.
If the trend continues, not out of the question. They have about $3.80 in cash, valuing the IP around $85 million. Very low--I think fair value is 200 million--but again not out of the question in this terrible market that's throwing the baby out with the bathwater.
Once ABUS broke LT support around 9, we've been in uncharted territory (no pun intended). There are no hard support/resistance points on the chart below 9, so it's anyone's guess. I based my prediction on a combination of cash on hand (~$200 million) and a reasonable valuation for their IP (another $200 million), putting SP around 7.50. I'd like to think this is the short-term bottom, but it's far from certain, especially in this sucky market. Good luck. -s
Not sure whre you got that number. Enterprise value (if that's what you mean) is $345 million or roughly $6.30 SP. I don't think we'll drop that low, but if the trend continues with both overall market weakness and biotech weakness, in particular, I think we will hit the 7.5 range near term.